PDS Biotechnology Entered Amended Sales Agreement With B. Riley And H.C. Wainwright; PDS Biotechnology Co May Sell From Time To Time Up To $50M In Common Stock Under New Agreement
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology has entered into an amended sales agreement with B. Riley and H.C. Wainwright, allowing the company to sell up to $50 million in common stock under the new agreement.
August 13, 2024 | 9:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PDS Biotechnology has amended its sales agreement with B. Riley and H.C. Wainwright, allowing the company to sell up to $50 million in common stock. This could provide the company with additional capital but may also dilute existing shares.
The amended sales agreement allows PDS Biotechnology to raise up to $50 million, which could be beneficial for funding operations and growth. However, the issuance of new shares may dilute the value of existing shares, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100